Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl

British Journal of Pharmacology

Volumn 117, Issue 8, 1996, Pages 1756-1760

  De La Cruz, Cristina P ^a   Revilla, Elisa ^a   Steffen, Vera ^a   Rodríguez Gómez, Jose A ^a   Cano, Josefina ^a   Machado, Alberto ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Aging; Deprenyl; Oxidative stress; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

CARBONYL DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

EID: 0029964328     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15350.x     Document Type: Article

References (37)

1. AGNATI, L.F., FUXE, K., BENFENATI, F., TOFFANO, G., CIMINO, M., CALZA, L., BATTISTINE, N. & PICH, E.M. (1984). Computer-assisted morphometry and microdensitometry of transmitter-identified neurons with special reference to the mesostriatal dopamine pathway. III Studies on aging processes. Acta Physiol. Scand. Suppl., 352, 45-64.
2. AHN, B., RHEE, S.G. & STADTMAN, E.R. (1987). Use of fluorescein hydrazide and fluorescein thiosemicarbazide reagents for the fluorometric determination of protein carbonyl groups and for the detection of oxidized protein on polyacrylamide gels. Anal. Biochem., 161, 245-257.
3. BIAGINI, G., ZOLI, M., FUXE, K. & AGNATI, L.F. (1993). L-deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. Neuro. Report, 4, 955-958.
4. BIRKMAYER, W., KNOLL, J., RIEDERER, P., HARS, V. & MARTON, J. (1985). Improvement of life expectancy due to L-deprenyl addition to madopar treatment in Parkinson's disease. J. Neural. Transm., 64, 113-127.
5. BRANDEIS, R., SAPIR, M., KAPON, Y., BORELLI, G., CADEL, S. & VALSECCHI, B. (1991). Improvement of cognitive function by MAO-B inhibitor L-Deprenyl in aged rats. Pharmacol. Biochem. Behav., 39, 297-304.
6. CARRILLO, M.C., KITANI, K., KANAI, S., SATO, Y., MIYASAKA, K. & IVY, G.O. (1994). The effect of a long-term (6 months) treatment with (-)Deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer-344 rats. Biochem. Pharmacol., 47, 1333-1338.
7. CASTAÑO, A., CANO, J. & MACHADO, A. (1993). Low selenium diet affects monoamine turnover in substantia nigra and striatum. J. Neurochem., 61, 1302-1307.
8. CESURA, A.M. & PLETSCHER, A. (1992). The new generation of monoamine oxidase inhibitors. Prog. Drug. Res., 38, 171-297.
9. COHEN, G. & SPINA, M.B. (1989). Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol., 26, 689-690.
10. DE LA CRUZ, C.P., REVILLA, E., VENERO, J.L., AYALA, A., CANO, J. & MACHADO, A. (1996). Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rats. Free Rad. Biol. Med., 20 53-61.
11. HARMAN, D. (1981). The aging process. Proc. Natl. Acad. Sci. U.S.A., 78, 7124-7128.
12. HEINONEN, E.H. & RINNE, U.K. (1989). Selegiline in the treatment of Parkinson's disease. Acta Neurol. Scand., 80 [Suppl], 103-111.
13. HEINONEN, E.H., SAVIJÄRVI, M., KOTILA, M., HAJBA, A. & SCHEININ, M. (1993). Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's deisease. J. Neural. Transm., [P-D Sect], 5, 193-202.
14. INGRAM, D.K., WIENER, H.L., CHACHICH, M.E., LONG, J.M., HENGEMIHLE, J. & GUPTA, M. (1993). Chronic treatment of aged mice with L-deprenyl produces marked striatal MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation. Neurobiol. Aging, 14, 431-440.
15. KITANI, K., KANAI, S., SATO, Y., OHTA, M., IVY, G.O. & CARRILLO, M.C. (1993). Chronic treatment of (-)Deprenyl prolongs the life span of male Fischer 344 rats. Life Sci., 52, 281-288.
16. KNOLL, J. (1978). The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J. Neural. Transm., 43, 177-198.
17. KNOLL, J. (1990). Nigrostriatal dopaminergic activity (-)deprenyl treatment and longevity. Adv. Neurol., 53, 425-429.
18. KNOLL, J. (1993). The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J. Neural. Transm., [Suppl] 40, 69-91.
19. KNOLL, J., TOTH, V., KUMMMERT, M. & SUGAR, J. (1992). (-)Deprenyl and parafluorodeprenyl treatment prevents age-related pigment changes in substantia nigra. A TV-image analysis of neuromelanin. Mech. Ageing Dev., 68, 157-163.
20. LAMOUR, Y., DUTAR, P. & JOBERT, A. (1987). Septo-hippocampal neurons: altered properties in the aged rat. Brain Res., 416, 277-282.
21. LENZ, A.G., COSTABEL, U., SHALTIEL, S. & LEVINE, R.L. (1989). Determination of carbonyl groups in oxidatively modified proteins by reduction with tritiated sodium borohydride. Anal. Biochem., 177, 419-425.
22. LI, X-M., QI, J., JUORIO, A.V. & BOULTON, A.A. (1993). Reduction in Glial Fibrillary Acidic Protein mRNA abundance induced by (-)-Deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells. J. Neurochem., 61, 1573-1576.
23. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
24. MILGRAM, N.W., RACINE, R.J., NELLIS, P., MENDONCA, A. & IVY, G.O. (1990). Maintenance on L-Deprenyl prolongs life in aged male rats. Life Sci., 47, 415-420.
25. MOGI, M., HARADA, M., KOJIMA, K., KIUCHI, K., NAGATSU, I. & NAGATSU, T. (1987). Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase activity in vitro and tyrosine hydroxylase content. Neurosci. Lett., 80, 213-218.
26. NAKAMURA, S., KAVAMATA, T., AKIGUCHI, I., KAMEYANA, M., NAKAMURA, N. & KIMURA, H. (1990). Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neurophathol., 80, 419-425.
27. PAXINOS, G. & WATSON, C. (1986). The Rat Brain in Stereotaxic Coordinates (second edition). San Diego: Academic Press.
28. 3H)tyrosine by charcoal. Life Sci., 39, 2185-2189.
29. RINNE, J.O., RÖYTTÄ, M., PALJÄRVI, L., RUMMUKAINEN, J. & RINNE, U.K. (1991). Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology, 41, 859-861.
30. STROLIN BENEDETTI, M. & DOSTERT, P. (1989). Monoamine oxidase, brain ageing and degenerative diseases. Biochem. Pharmacol., 38, 555-561.
31. TATTON, W.G. & GREENWOOD, C.E. (1991). Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci., 30, 666-672.
32. TERTRUD, J.W. & LANGSTON, J.W. (1989). The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science, 245, 519-522.
33. THE PARKINSON STUDY GROUP. (1993). Effect of tocopherol deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med., 328, 176-183.
34. VIZUETE, M.L., STEFFEN, V., AYALA, A., CANO, J. & MACHADO, A. (1993). Protective effect of deprenyl against 1-methyl-4-phenyl-pyridinium neurotoxicity in rat striatum. Neurosci. Lett., 152, 113-116.
35. VRANA, S.L., VRANA, K.E., KOVES, T.R., SMITH, J.E. & DWORKIN, S.I. (1993). Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. J. Neurochem., 61, 2262-2268.
36. WOLF, M.E., LEWITT, P.A., BANNON, M.J., DRAGOVIC, L.J. & KAPATOS, G. (1991). Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate. J. Neurochem., 56, 1191-1200.
37. ZSILLA, G., FOLDI, P., HELD, G., SZ'KELY, A.M. & KNOLL, J. (1986). The effect of repeated doses of (-)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol. J. Pharmacol. Pharm., 38, 57-67.